Drug General Information
Drug ID	D0U0AU
Former ID	DIB010721
Drug Name	AZD-9819
Synonyms	Neutrophil elastase inhibitor (inhaled, COPD), AstraZeneca
Indication	Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47]		Phase 1	[523120]
Company	AstraZeneca plc
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Leukocyte elastase	Target Info	Inhibitor	[533294]
KEGG Pathway	Transcriptional misregulation in cancer
	Systemic lupus erythematosus
Pathway Interaction Database	Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
	C-MYB transcription factor network
Reactome	Collagen degradation
	Degradation of the extracellular matrix
	Activation of Matrix Metalloproteinases
WikiPathways	Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
	Human Complement System
	Degradation of collagen
References
Ref 523120	ClinicalTrials.gov (NCT01166698) Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects. U.S. National Institutes of Health.
Ref 533294	Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.